Document is current
Any future updates will be listed below
-
Authors
Simhal, Anish K. https://orcid.org/0000-0001-7848-3565
Firestone, Ross S. https://orcid.org/0000-0002-2945-9320
Oh, Jung Hun
Avutu, Viswatej
Norton, Larry
Hultcrantz, Malin https://orcid.org/0000-0002-9045-6495
Usmani, Saad Z. https://orcid.org/0000-0002-5484-8731
Maclachlan, Kylee H. https://orcid.org/0000-0001-7873-4854
Deasy, Joseph O.
-
Funding
Funding for this research was provided by:
Simons Foundation
Breast Cancer Research Foundation
Conquer Cancer Foundation
- License Information
-
More Information
Article History
Received: 18 September 2024
Revised: 9 January 2025
Accepted: 29 January 2025
First Online: 20 February 2025
Competing interests
: SZU: research funding: Amgen, BMS/Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, Takeda. Consulting/Advisory Board: AbbVie, Amgen, BMS, Celgene, Genentech, Gilead, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
